IntelliCell BioSciences To Open Adipose Tissue Processing Centre in Houston
IntelliCell BioSciences, Inc. (OTCQB: SVFC), maker of stromal vascular fraction that contains adipose derived adult stem cells, said it has signed a deal to open an adipose stem cell processing center in Houston, Texas.
The plant, which the company plans to open in the next six weeks, would make adipose derived stem cells available for doctors in the metro Houston area.
No financial terms or conditions were disclosed in the press release.
IntelliCell BioSciences, Inc. (OTCQB: SVFC), maker of stromal vascular fraction that contains adipose derived adult stem cells, said it has signed a deal to open an adipose stem cell processing center in Houston, Texas.
The plant, which the company plans to open in the next six weeks, would make adipose derived stem cells available for doctors in the metro Houston area.
No financial terms or conditions were disclosed in the press release.
The company said the use of autologous adipose stem cells for a growing variety of indications is a new and exciting frontier in medicine. The aesthetic use of autologous adipose stem cells has become widely accepted in Europe and Asia, it added.
Currently, many companies and researchers are studying the use of adipose stem cells for aesthetics, arthritis, and orthopedic injuries such as knees, elbows, back and shoulders, congestive heart failure, among other ailments.
Since 2009 when the Food and Drug Administration published its laws on autologous stem cells the field has expanded rapidly, the company said.
“The company’s entry into the Houston market will grant us the opportunity to offer this community of physicians, researchers, and healthcare centers access to the highest number and quality stromal vascular fraction cells which contain adult stem cells through our proprietary, FDA compliant process,” said IntelliCell BioSciences officials.
New York City-based IntelliCell has processing centers in New York City, Philadelphia, Dallas, and New Orleans.
The company said it intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities.–Brad Lemaire
